Investing.com
September 24, 2024
By Scott Kanowsky
Number of Ozempic side effects lawsuits centralized in PA court expanding
Summary of article:
A growing number of personal injury lawsuits in Pennsylvania are targeting popular weight-loss drugs developed by Novo Nordisk and Eli Lilly, specifically their GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro. These claims, now centralized in a multidistrict litigation (MDL) in Pennsylvania court,, accuse the drugmakers of failing to warn patientsnot adequately warning users about the potential gastrointestinal side effects associated with the medications. Despite being grouped in federal court, plaintiffs can still file similar lawsuits in state courts.
Alexandra Walsh, a partner at Anapol Weiss, is representing plaintiffs in these cases and has confirmed that over 1,025 cases have already been filed, mostly focused on the gastrointestinal damage allegedly caused by these drugs.
Walsh emphasizes that the lawsuits highlight a failure by the companies to provide clear and balanced information about the potential risks of the GLP-1 drugs. "The companies behind GLP-1 medications should at a minimum give people fair, balanced, and accurate information about the downsides," Walsh stated, stressing the importance of informed decision-making between patients and their doctors. She further added, "Patients deserve transparency, especially when it comes to the long-term effects of medications like these. The lack of adequate warnings is at the heart of these cases."
GLP-1 drugs, initially developed to help diabetic patients control blood sugar, have also been marketed for their weight-loss benefits, leading to blockbuster sales and projections of annual global sales reaching $150 billion in the coming decade.
To learn more about the Ozempic lawsuits, click here.
Read the full article here.
